Jazz Pharmaceuticals has received the green light for Ziihera as a first-line treatment for HER2-positive advanced gastric cancer. The approval opens up a significantly larger market for the drug, which the company believes could achieve peak sales of more than $2bn.
After more than a decade with trastuzumab (Herceptin) as the backbone of HER2-targeted treatment for advanced gastric cancer, doctors in the US now have a new option.
The US Food and Drug Administration (FDA) has approved Jazz Pharmaceuticals’ bispecific antibody Ziihera (zanidatamab) as a first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma (GEA).
BREAKING